Company intelligence / Profile preview

Orphazyme

Ownership: Public · ORPH
Employees: ~17
Development stage: Other

Overview

Orphazyme was a Danish biopharmaceutical company developing small molecule therapies targeting heat shock protein pathways for rare neurodegenerative and lysosomal storage diseases. Its lead candidate arimoclomol advanced through late-stage clinical trials and reached NDA submission for Niemann-Pick disease type C but failed to secure regulatory approval. The company subsequently underwent restructuring and changed its name to Strategic Partners A/S.

Therapeutic areas: Rare DiseasesMetabolic DisordersNeurology
Modalities: Small moleculeProtein therapy
Industry: Biotech

Drug pipeline

1 asset

Orph-001

Preclinical

Partnerships

Collaborations with academic institutions in Europe and the United States

Financials

Market cap: $0
Total revenue: $0
Enterprise value: $-17.8M

Beyond the preview

Go deeper on Orphazyme.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orphazyme.

Explore the full profile